Morphine Milligram Equivalents: Why a Dose Is Not a Diagnosis

Morphine milligram equivalents convert each opioid into one morphine-sized figure, so different drugs add into a daily total. The number measures dose, not what is causing the pain. A fifty-eight-year-old man with arachnoiditis had been stable for six years. On that number, his dose was cut in half within eight weeks. He landed in an emergency room in withdrawal.

A fifty-eight-year-old man with arachnoiditis kept a warehouse job for six years on a stable dose. Then a quality report flagged his physician’s practice. His dose was cut in half within eight weeks. By week nine he was in an emergency room in withdrawal. One figure had steered every decision about him: a total in morphine milligram equivalents. Nothing on his chart said what was causing his pain.

The video above, A Dose Is Not a Diagnosis, is Chapter 17 of The Pained Brain by Dr. Gurpreet Singh Padda, MD, MBA, MHP, and Dr. KrisJay Fucanan, MD. Below: how the unit is figured, why it is shaky, and what the tapering research shows on both sides.

What morphine milligram equivalents are meant to measure

A morphine milligram equivalent, or MME, converts each opioid into one morphine-sized figure. That way different drugs can be added into a daily total. Risk does rise with dose. A Washington health plan cohort, published in 2010, followed 9,940 patients on opioids for chronic pain. Those taking 100 milligrams or more a day had 8.9 times the overdose rate of those taking 1 to 20.

Read the same study for its absolute numbers and the picture shifts. The yearly overdose rate was 0.2 percent at the low dose and 1.8 percent at the high dose. Only 1.8 percent of the time watched was spent at 100 milligrams or more. The authors wrote that most overdoses happened on low to middle doses. When the dose studies were later pooled, overdose risk began climbing at 20 milligrams a day. There is no cliff at 90. There is a ramp that begins with the first tablet.

How a voluntary sentence became a pharmacy alert

The 2016 federal guideline told doctors to avoid raising doses to 90 MME or more, or to justify it with care. It said patients already above that line should be offered a chance to rethink. It called its advice voluntary. Then groups with no patients took the wheel. A quality-scoring group lowered its own line from 120 to 90 in 2019. It turned the sentence into a health-plan score where a lower rate counts as better. Medicare told drug plans to put a block at the pharmacy counter at 90. By mid-2017, 22 states had some kind of dose-limit policy. The lines ran anywhere from 30 to 300 milligrams.

That spread tells you the line is not a fact of biology. Medicare’s own record shows what happened when a hard stop sat at 200. Of the members who hit it, 93 percent asked for a coverage decision, and most were approved. The block found paperwork, not dangerous patients. A plan scored on a percentage has every money reason to move the percentage, whatever happens to the person inside it.

A unit that clinicians cannot agree on

In one test, 319 doctors converted the same doses. A 75-microgram fentanyl patch came out at an average of 176 milligrams, give or take 117. And 40 milligrams of methadone came out at 193, give or take 201. Eight online calculators disagreed on one dose by anywhere from minus 55 percent to plus 242 percent. Only 27 percent of published studies say which conversion they used. Four fair ways to define a daily dose moved the share of high-dose patients in one state’s data from 5.9 to 14.2 percent.

Then the milligram enters a body. The liver enzyme CYP2D6 turns codeine and tramadol into their active form. Poor metabolizers (slow processors) get 96 percent less morphine from a codeine dose. Ultrarapid metabolizers (very fast processors) get 45 percent more. After knee and hip replacement, one opioid receptor gene changed how much morphine people needed. Its effect flipped direction based on whether the patient had diabetes. Enzymes set how much drug a tablet becomes. The insulin behind diabetes changes what that drug does once it arrives.

Dose is a weak predictor of overdose

In a Medicare cohort, dose-based safety checks caught 29.29 percent of the people who later overdosed. A model using dose plus 267 other factors caught 90 percent. Dose was the strongest single predictor, and still only one of 268. Among patients starting a first prescription, a substance-use disorder raised overdose risk 2.74-fold. Age over 75 raised it 3.22-fold. Adding a benzodiazepine raised the hazard 5.05-fold in the first 90 days.

What tapering did, and what it did not do

The evidence runs both ways, and both sides deserve a hearing. Take 1,394,102 veterans. Those treated longest had a hazard of 6.77 for death by overdose or suicide after their opioids were stopped. Monthly cuts faster than 30 percent carried a hazard of 5.33 for overdose the next month. Cuts of 10 percent or less carried none. One trial emulation (a study built to mimic a trial) looked at stable patients. Their eleven-month risk of overdose or suicide ran 0.96 percent when nothing changed. It ran 1.10 percent after a taper and 1.28 percent after a sudden stop.

On the other side, Oregon Medicaid patients had lower overdose risk after discontinuation, and in Australia, stopping was linked with lower fatal overdose and no change in suicide. Taken together, the danger does not live in the milligram. It lives in how the change is made: its speed, the loss of a physician, the lack of a plan. A simulated patient on a stable dose phoned primary-care clinics. Of them, 40.7 percent said they would not prescribe. The damage from rushed, unsupported cuts is laid out in why abrupt opioid tapering is also harm, and the mortality data that frame it are in what the death data show about chronic pain.

The strongest case for strict limits

Prescribing per person peaked in 2010 at 782 MME and in 2015 was still three times the 1999 level. Deaths have fallen, from 110,037 in 2023 to 69,973 in 2025. Prescribing was too high, and a physician who dismisses that is not being honest either.

The rest of the record matters as much. In 2023, deaths from prescription-type opioids ran 2.9 per 100,000 against 22.2 for illicit synthetics. Across 32 states, prescribing-cap laws changed neither prescribing nor overdose. The risk also moved sideways: gabapentin was detected in 9.7 percent of overdose deaths across 23 states. The rules worked mostly on people who already had a prescription.

Treat the generator so the dose can fall

The way out is not to win the argument about the number. It is to remove the reason for it. In 191 English primary-care practices, a voluntary group program ran with a year of nurse and peer support. It got 29 percent of people off opioids, against 7 percent with usual care. Pain did not get in the way of life any more than before. The veterans’ system once required a team case review instead of a cut. Stopping fell 11.16 percentage points, and deaths from all causes fell 3.31. Keeping the patient in care is itself a treatment.

For this man, test blocks were positive at two facet joints and the sacroiliac joint. That is how medial branch blocks and ablation are supposed to work: prove the generator, then treat it. Ablation followed, done awake. So did the unglamorous part. His fasting insulin was 31 and a sleep study found apnea. So he changed how he ate and started walking. That work targets the insulin that changes what a milligram does. It also targets the sleep an opioid’s effect depends on. Over eleven months, by his choice and at his pace, his dose settled at 40 milligrams. Arachnoiditis does not go away, and the goal was never zero. How blocks prove a joint is the source is covered in the post on diagnostic blocks.

In my practice, new patients average above 90 MME a day. Under interventional treatment, 21 percent of them are fully off opioids within 90 days and 34 percent within a year. Under 1 percent of our long-term patients stay above 90. These are figures from our own practice, not trial results, and each person’s result varies. What the cheapest treatment really costs is the subject of the four-dollar bottle post. The evidence behind every figure, graded honestly, is in the Chapter 17 Deep Dive.

Frequently asked questions

What does MME mean on a prescription record?

MME stands for morphine milligram equivalents. It converts each opioid into the amount of morphine thought to have a similar effect. That way different drugs can be added into one daily total. The conversion is less exact than it looks. Doctors given the same doses came up with very different answers. And buprenorphine should not be counted in the total at all. Sedatives taken alongside often matter more. That is why we ask patients to come off one of them.

Is 90 MME a dangerous dose?

Risk rises with dose, but as a slope, not a step. Pooled dose studies found overdose risk starting to climb at 20 milligrams a day. The 2016 guideline called 90 a line to avoid crossing or to justify. It was not an order to cut long-term patients. How dose changes fit into a larger plan is explained in medication as a bridge during opioid tapering.

Do dosage thresholds require a physician to lower a stable dose?

The agencies that wrote them say no. Federal guidance warns doctors not to misread warning lines as orders to cut doses. Medicare says its pharmacy blocks should not act as a prescribing limit or replace a doctor’s judgment. Access still suffered. A simulated patient on a stable dose called clinics, and 40.7 percent said they would not prescribe. That access gap is documented in research on patients who struggle to find a new physician.

How fast is too fast when a dose is reduced?

For people on long-term opioids, cutting more than 30 percent in a month was tied to a 5.33 hazard of overdose the next month. Cuts of 10 percent or less showed no added hazard. Any change belongs in a written plan with your prescribing physician. The plan should say who decides when to pause. Untreated metabolic drivers can keep pain high and make any plan harder. See how high insulin makes you hurt.

Are non-opioid pain relievers automatically safer?

Swapping drugs is a trade. In the year after the 2016 guideline, prescriptions for non-opioid pain drugs ran above the past trend. Gabapentin turned up in 9.7 percent of overdose deaths across 23 states. And ketorolac carried an odds ratio of 20.67 for stomach and gut bleeding. Every alternative has its own risks to weigh with your physician. For the stomach, see what long-term NSAIDs do to the gut.

Sources

1. Dunn, K. M., Saunders, K. W., Rutter, C. M., Banta-Green, C. J., Merrill, J. O., Sullivan, M. D., Weisner, C. M., Silverberg, M. J., Campbell, C. I., Psaty, B. M., & Von Korff, M. (2010). Opioid prescriptions for chronic pain and overdose: a cohort study. Annals of Internal Medicine, 152(2), 85–92. https://doi.org/10.7326/0003-4819-152-2-201001190-00006
2. Dowell, D., Haegerich, T. M., & Chou, R. (2016). CDC Guideline for Prescribing Opioids for Chronic Pain–United States, 2016. JAMA, 315(15), 1624–1645. https://doi.org/10.1001/jama.2016.1464
3. Rennick, A., Atkinson, T., Cimino, N. M., Strassels, S. A., McPherson, M. L., & Fudin, J. (2016). Variability in Opioid Equivalence Calculations. Pain Medicine, 17(5), 892–898. https://doi.org/10.1111/pme.12920
4. Crews, K. R., Monte, A. A., Huddart, R., Caudle, K. E., Kharasch, E. D., Gaedigk, A., Dunnenberger, H. M., Leeder, J. S., Callaghan, J. T., Samer, C. F., Klein, T. E., Haidar, C. E., Van Driest, S. L., Ruano, G., Sangkuhl, K., Cavallari, L. H., Müller, D. J., Prows, C. A., Nagy, M., … Skaar, T. C. (2021). Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clinical Pharmacology and Therapeutics, 110(4), 888–896. https://doi.org/10.1002/cpt.2149
5. Lo-Ciganic, W.-H., Huang, J. L., Zhang, H. H., Weiss, J. C., Wu, Y., Kwoh, C. K., Donohue, J. M., Cochran, G., Gordon, A. J., Malone, D. C., Kuza, C. C., & Gellad, W. F. (2019). Evaluation of Machine-Learning Algorithms for Predicting Opioid Overdose Risk Among Medicare Beneficiaries With Opioid Prescriptions. JAMA Network Open, 2(3), e190968. https://doi.org/10.1001/jamanetworkopen.2019.0968
6. Oliva, E. M., Bowe, T., Manhapra, A., Kertesz, S., Hah, J. M., Henderson, P., Robinson, A., Paik, M., Sandbrink, F., Gordon, A. J., & Trafton, J. A. (2020). Associations between stopping prescriptions for opioids, length of opioid treatment, and overdose or suicide deaths in US veterans: observational evaluation. BMJ, 368, m283. https://doi.org/10.1136/bmj.m283
7. Glanz, J. M., Xu, S., Narwaney, K. J., McClure, D. L., Rinehart, D. J., Ford, M. A., Nguyen, A. P., & Binswanger, I. A. (2023). Association Between Opioid Dose Reduction Rates and Overdose Among Patients Prescribed Long-Term Opioid Therapy. Substance Abuse, 44(3), 209–219. https://doi.org/10.1177/08897077231186216
8. Larochelle, M. R., Lodi, S., Yan, S., Clothier, B. A., Goldsmith, E. S., & Bohnert, A. S. B. (2022). Comparative Effectiveness of Opioid Tapering or Abrupt Discontinuation vs No Dosage Change for Opioid Overdose or Suicide for Patients Receiving Stable Long-term Opioid Therapy. JAMA Netw Open, 5(8), e2226523. https://doi.org/10.1001/jamanetworkopen.2022.26523
9. Sandhu, H. K., Booth, K., Furlan, A. D., Shaw, J., Carnes, D., Taylor, S. J. C., Abraham, C., Alleyne, S., Balasubramanian, S., Betteley, L., Haywood, K. L., Iglesias-Urrutia, C. P., Krishnan, S., Lall, R., Manca, A., Mistry, D., Newton, S., Noyes, J., Nichols, V., … Underwood, M. (2023). Reducing Opioid Use for Chronic Pain With a Group-Based Intervention: A Randomized Clinical Trial. JAMA, 329(20), 1745–1756. https://doi.org/10.1001/jama.2023.6454
10. Li, Y., Barr, K. D., Trafton, J. A., Oliva, E. M., Garrido, M. M., Frakt, A. B., & Strombotne, K. L. (2023). Impact of Mandated Case Review Policy on Opioid Discontinuation and Mortality Among High-Risk Long-Term Opioid Therapy Patients: The STORM Stepped-Wedge Cluster Randomized Controlled Trial. Subst Abus, 44(4), 292–300. https://doi.org/10.1177/08897077231198299

Medically reviewed by Dr. Gurpreet Singh Padda, MD, MBA, MHP, board certified in anesthesiology, pain medicine, interventional pain management, addiction medicine and obesity medicine. Adapted from Chapter 17 of The Pained Brain by Dr. Padda and Dr. KrisJay Fucanan, MD. Last reviewed September 2026.

Dr. Gurpreet Singh Padda, MD, MBA, MHP